ES2135663T3 - Administracion mucosal de antigenos de pneumococos. - Google Patents

Administracion mucosal de antigenos de pneumococos.

Info

Publication number
ES2135663T3
ES2135663T3 ES95303365T ES95303365T ES2135663T3 ES 2135663 T3 ES2135663 T3 ES 2135663T3 ES 95303365 T ES95303365 T ES 95303365T ES 95303365 T ES95303365 T ES 95303365T ES 2135663 T3 ES2135663 T3 ES 2135663T3
Authority
ES
Spain
Prior art keywords
mucosal administration
pneumococos
antigens
pneumococal
colonization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95303365T
Other languages
English (en)
Inventor
David E Briles
Hong-Yin Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/246,636 external-priority patent/US5965141A/en
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Application granted granted Critical
Publication of ES2135663T3 publication Critical patent/ES2135663T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA ADMINISTRACION MUCOSAL, PARTICULARMENTE DE FORMA INTRANASAL, DE NEUMOCOCOS COMPLETOS, MUERTOS, LISATOS DE NEUMOCOCOS Y PSPA AISLADA Y PURIFICADA, ASI COMO FRAGMENTOS INMUNOGENICOS DE LOS MISMOS, PARTICULARMENTE CUANDO SE ADMINISTRAN CON UNA SUBUNIDAD DE LA TOXINA B DEL COLERA, SUMINISTRA PROTECCION EN LOS ANIMALES CONTRA LA COLONIZACION NEUMOCOCAL Y LA INFECCION SISTEMICA. LA CAPACIDAD PARA PRODUCIR PROTECCION CONTRA LA COLONIZACION NEUMOCOCAL EN UN ANFITRION EVITA EL TRANSPORTE ENTRE INDIVIDUOS INMUNIZADOS, QUE PUEDEN DIRIGIRSE A LA ELIMINACION DE LA ENFERMEDAD DE TODA LA POBLACION.
ES95303365T 1994-05-20 1995-05-19 Administracion mucosal de antigenos de pneumococos. Expired - Lifetime ES2135663T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/246,636 US5965141A (en) 1991-02-15 1994-05-20 Epitopic regions of pneumococcal surface protein a
US08/312,949 US6027734A (en) 1991-02-15 1994-09-30 Mucosal administration of pneumococcal antigens

Publications (1)

Publication Number Publication Date
ES2135663T3 true ES2135663T3 (es) 1999-11-01

Family

ID=26938117

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95303365T Expired - Lifetime ES2135663T3 (es) 1994-05-20 1995-05-19 Administracion mucosal de antigenos de pneumococos.

Country Status (13)

Country Link
US (1) US6027734A (es)
EP (1) EP0682950B1 (es)
JP (1) JP2747435B2 (es)
AT (1) ATE182270T1 (es)
AU (1) AU698724B2 (es)
CA (1) CA2149703A1 (es)
DE (1) DE69510858T2 (es)
DK (1) DK0682950T3 (es)
ES (1) ES2135663T3 (es)
FI (1) FI952445A7 (es)
GR (1) GR3031491T3 (es)
IL (1) IL113772A0 (es)
NO (1) NO951982L (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU709368B2 (en) * 1995-06-02 1999-08-26 Uab Research Foundation Oral administration of pneumococcal antigens
ZA964896B (en) * 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
US7078042B2 (en) * 1995-09-15 2006-07-18 Uab Research Foundation Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
EP1067962B1 (en) * 1998-04-07 2010-03-24 MedImmune, LLC Derivatives of pneumococcal choline binding proteins for vaccines
US20010016200A1 (en) * 1998-04-23 2001-08-23 Briles David E. Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
AU2001224429A1 (en) * 2000-09-29 2002-04-15 Genomics Collaborative, Inc. Methods of diagnosing community acquired pneumonia (cap) and predisposition or susceptibility for cap and associated septic shock through detection of gene polymorphisms
KR100965026B1 (ko) 2002-02-13 2010-06-21 이뮤놀로지 래보러토리스 인코포레이티드 미생물 감염증을 치료하기 위한 조성물 및 방법
AU2004269320B2 (en) 2003-06-20 2009-12-24 Protein Sciences Corporation Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using
CN1909921B (zh) * 2003-11-10 2012-09-26 Uab研究基金会 减少细菌携带和中枢神经系统侵害的组合物及其使用方法
EP2059807B1 (en) * 2006-08-17 2013-02-20 The UAB Research Foundation Diagnosing pneumococcal pneumonia
MX2009012676A (es) 2007-05-23 2010-02-12 Uab Research Foundation Neuraminidasa neumococica no toxica y sus usos.
JP5854537B2 (ja) 2012-09-19 2016-02-09 国立大学法人大阪大学 肺炎球菌表面タンパク質ａを含む肺炎球菌ワクチン
US11053532B2 (en) 2017-04-19 2021-07-06 CAP Diagnostics, LLC Methods for treating polymicrobial infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6444889U (es) * 1987-09-14 1989-03-17
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
ATE168132T1 (de) * 1991-02-15 1998-07-15 Uab Research Foundation Strukturgen von pneumokokken-protein
AU5958594A (en) * 1992-12-24 1994-07-19 Med Immune, Inc. Method of protection against (streptococcus pneumoniae) with transformed mycobacteria
CA2116261A1 (en) * 1993-04-20 1994-10-21 David E. Briles Epitopic regions of pneumococcal surface protein a

Also Published As

Publication number Publication date
EP0682950A1 (en) 1995-11-22
FI952445L (fi) 1995-11-21
CA2149703A1 (en) 1995-11-21
NO951982D0 (no) 1995-05-19
DE69510858D1 (de) 1999-08-26
AU698724B2 (en) 1998-11-05
FI952445A7 (fi) 1995-11-21
NO951982L (no) 1995-11-21
IL113772A0 (en) 1995-08-31
GR3031491T3 (en) 2000-01-31
ATE182270T1 (de) 1999-08-15
DE69510858T2 (de) 2000-04-13
US6027734A (en) 2000-02-22
JPH0840927A (ja) 1996-02-13
DK0682950T3 (da) 1999-11-29
AU2015095A (en) 1995-11-30
EP0682950B1 (en) 1999-07-21
JP2747435B2 (ja) 1998-05-06
FI952445A0 (fi) 1995-05-19

Similar Documents

Publication Publication Date Title
ES2170771T3 (es) Atenuacion de un epitopo inmunodominante de un antigeno para su utilizacion en vacunas e inmunoterapias para vegetales, animales y humanos.
ES2091737T1 (es) Formulados farmaceuticos de fluoxetina.
ES2152421T3 (es) Vacunas de conjugados polisacarido neumococcico-neumolisina recombinante para la inmunizacion contra las infecciones neumococcicas.
MX9307686A (es) Preparacion de liberacion sostenida.
ES2051013T3 (es) Procedimiento de preparacion de compuesto ligando-receptor.
AR030829A1 (es) Una formulacion de vacuna, procedimiento para la produccion de la misma, uso de dicha preparacion y un estuche para su administracion via intranasal
ES2148247T3 (es) Procedimiento de preparacion de liofilizado de cetrorelix.
ES2174248T3 (es) Composiciones para la eliminacion de una placa dental.
DK1024824T3 (da) Dispergerende vaccinesammensætning i fast form til oral indgivelse
ES2130205T3 (es) Bigudi para permanentes.
AR036937A1 (es) Tableta masticable que contiene lisina
ES2151517T3 (es) Efectos de filamentos de actina sobre la estructura y lisis de coagulos de fibrina.
ES2079327A1 (es) Formulaciones farmaceuticas de cefaclor.
ES2192559T3 (es) Vacuna para la proteccion de aves de corral contra la coccidiosis.
ATE182270T1 (de) Mukosale verabreichung von pneumokokken-antigenen
ES2166900T3 (es) Derivados de ara-c.
AR036755A1 (es) Una composicion en forma de gel transparente para la administracion de diclofenac sodico a traves de la piel
AR015230A1 (es) Composicion cosmetica que contiene un compuesto de actividad estimuladora de la produccion de interleuquina-6, cepa rhodotorula sebr 2002, procedimiento depreparacion de un extracto, composicion obtenida, utilizacion de un compuesto de actividad estimuladora y metodo de tratamiento cosmetico.
AR023643A1 (es) Formulaciones de vacuna de multiples antigenos
DE69822098D1 (de) Sonnenschutzmittel die beschädigte rns fragmente enthälten
NO20002428D0 (no) Hudpreparat
ES2059605T3 (es) Vacuna toxoide de la tosferina.
ES2167576T3 (es) Terpenos para la reduccion del efecto de feromonas sobre lepidopteros.
ITTO920116A1 (it) Profilattico autoadesivo orale esterno
Sajjad et al. Case Report: Insect Bite Reveals Botfly Myiasis in an Older Woman

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 682950

Country of ref document: ES